vs
STANDARD BIOTOOLS INC.（LAB）与MainStreet Bancshares, Inc.（MNSB）财务数据对比。点击上方公司名可切换其他公司
MainStreet Bancshares, Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.7倍（$32.8M vs $19.6M），MainStreet Bancshares, Inc.同比增速更快（-8.8% vs -11.5%），MainStreet Bancshares, Inc.自由现金流更多（$10.6M vs $-23.1M），过去两年MainStreet Bancshares, Inc.的营收复合增速更高（-0.7% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
MainStreet Bancshares, Inc.是一家总部位于美国的银行控股公司，提供全面的零售及商业银行服务，涵盖存款产品、个人及商业贷款、房屋抵押贷款、财富管理方案，主要服务个人消费者、中小型企业及区域社区客户。
LAB vs MNSB — 直观对比
营收规模更大
MNSB
是对方的1.7倍
$19.6M
营收增速更快
MNSB
高出2.7%
-11.5%
自由现金流更多
MNSB
多$33.7M
$-23.1M
两年增速更快
MNSB
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $32.8M |
| 净利润 | $-34.7M | — |
| 毛利率 | 48.5% | 55.1% |
| 营业利润率 | -168.5% | 14.9% |
| 净利率 | -177.4% | — |
| 营收同比 | -11.5% | -8.8% |
| 净利润同比 | -28.8% | — |
| 每股收益（稀释后） | $-0.09 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABMNSB
| Q4 25 | — | $32.8M | ||
| Q3 25 | $19.6M | $33.6M | ||
| Q2 25 | $21.8M | $35.4M | ||
| Q1 25 | $40.8M | $33.9M | ||
| Q4 24 | — | $35.9M | ||
| Q3 24 | $22.1M | $34.5M | ||
| Q2 24 | $22.5M | $34.2M | ||
| Q1 24 | $45.5M | $33.3M |
净利润LABMNSB
| Q4 25 | — | — | ||
| Q3 25 | $-34.7M | $4.5M | ||
| Q2 25 | $-33.5M | $4.6M | ||
| Q1 25 | $-26.0M | $2.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-26.9M | $265.0K | ||
| Q2 24 | $-45.7M | $2.6M | ||
| Q1 24 | $-32.2M | $3.3M |
毛利率LABMNSB
| Q4 25 | — | 55.1% | ||
| Q3 25 | 48.5% | 54.3% | ||
| Q2 25 | 48.8% | 56.2% | ||
| Q1 25 | 48.4% | 51.5% | ||
| Q4 24 | — | 46.9% | ||
| Q3 24 | 54.9% | 47.1% | ||
| Q2 24 | 46.1% | 47.7% | ||
| Q1 24 | 53.1% | 49.4% |
营业利润率LABMNSB
| Q4 25 | — | 14.9% | ||
| Q3 25 | -168.5% | 16.1% | ||
| Q2 25 | -118.1% | 16.0% | ||
| Q1 25 | -80.8% | 9.2% | ||
| Q4 24 | — | -4373.3% | ||
| Q3 24 | -120.9% | 0.3% | ||
| Q2 24 | -134.5% | 8.4% | ||
| Q1 24 | -132.2% | 12.4% |
净利率LABMNSB
| Q4 25 | — | — | ||
| Q3 25 | -177.4% | 13.4% | ||
| Q2 25 | -153.7% | 13.0% | ||
| Q1 25 | -63.8% | 7.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | -122.0% | 0.8% | ||
| Q2 24 | -203.3% | 7.7% | ||
| Q1 24 | -70.6% | 9.9% |
每股收益（稀释后）LABMNSB
| Q4 25 | — | $0.46 | ||
| Q3 25 | $-0.09 | $0.52 | ||
| Q2 25 | $-0.09 | $0.53 | ||
| Q1 25 | $-0.07 | $0.25 | ||
| Q4 24 | — | $-2.19 | ||
| Q3 24 | $-0.07 | $-0.04 | ||
| Q2 24 | $-0.12 | $0.27 | ||
| Q1 24 | $-0.27 | $0.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $218.6M |
| 总资产 | $539.6M | $2.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABMNSB
| Q4 25 | — | — | ||
| Q3 25 | $129.4M | — | ||
| Q2 25 | $158.6M | — | ||
| Q1 25 | $150.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $210.6M | — | ||
| Q2 24 | $269.8M | — | ||
| Q1 24 | $287.1M | — |
总债务LABMNSB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABMNSB
| Q4 25 | — | $218.6M | ||
| Q3 25 | $399.7M | $218.4M | ||
| Q2 25 | $424.5M | $213.5M | ||
| Q1 25 | $454.6M | $209.6M | ||
| Q4 24 | — | $208.0M | ||
| Q3 24 | $489.3M | $226.1M | ||
| Q2 24 | $510.3M | $224.7M | ||
| Q1 24 | $577.3M | $223.1M |
总资产LABMNSB
| Q4 25 | — | $2.2B | ||
| Q3 25 | $539.6M | $2.1B | ||
| Q2 25 | $557.0M | $2.1B | ||
| Q1 25 | $579.6M | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | $681.5M | $2.2B | ||
| Q2 24 | $708.7M | $2.1B | ||
| Q1 24 | $777.7M | $2.1B |
负债/权益比LABMNSB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $14.8M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $10.6M |
| 自由现金流率自由现金流/营收 | -118.1% | 32.5% |
| 资本支出强度资本支出/营收 | 4.5% | 12.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $14.9M |
8季度趋势，按日历期对齐
经营现金流LABMNSB
| Q4 25 | — | $14.8M | ||
| Q3 25 | $-22.2M | $5.6M | ||
| Q2 25 | $-20.7M | $1.2M | ||
| Q1 25 | $-30.3M | $1.5M | ||
| Q4 24 | — | $14.7M | ||
| Q3 24 | $-27.9M | $4.5M | ||
| Q2 24 | $-39.0M | $1.2M | ||
| Q1 24 | $-62.5M | $3.6M |
自由现金流LABMNSB
| Q4 25 | — | $10.6M | ||
| Q3 25 | $-23.1M | $5.5M | ||
| Q2 25 | $-22.6M | $-2.6M | ||
| Q1 25 | $-35.3M | $1.4M | ||
| Q4 24 | — | $13.8M | ||
| Q3 24 | $-30.1M | $4.3M | ||
| Q2 24 | $-41.0M | $1.1M | ||
| Q1 24 | $-63.3M | $3.0M |
自由现金流率LABMNSB
| Q4 25 | — | 32.5% | ||
| Q3 25 | -118.1% | 16.2% | ||
| Q2 25 | -103.6% | -7.4% | ||
| Q1 25 | -86.6% | 4.1% | ||
| Q4 24 | — | 38.5% | ||
| Q3 24 | -136.4% | 12.5% | ||
| Q2 24 | -182.2% | 3.1% | ||
| Q1 24 | -138.9% | 9.1% |
资本支出强度LABMNSB
| Q4 25 | — | 12.7% | ||
| Q3 25 | 4.5% | 0.4% | ||
| Q2 25 | 8.7% | 10.8% | ||
| Q1 25 | 12.4% | 0.2% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | 10.2% | 0.5% | ||
| Q2 24 | 8.6% | 0.3% | ||
| Q1 24 | 1.7% | 1.8% |
现金转化率LABMNSB
| Q4 25 | — | — | ||
| Q3 25 | — | 1.24× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | — | 0.59× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 16.87× | ||
| Q2 24 | — | 0.45× | ||
| Q1 24 | — | 1.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
MNSB
暂无分部数据
